Warning about Hemolysis with WinRho SDF

Baxter Healthcare and Cangene are alerting healthcare professionals about new warnings for WinRho SDF, an IGIV product used to treat patients with immune thrombocytopenic purpura (ITP).

In rare cases, ITP patients being treated with WinRho SDF have experienced severe intravascular hemolysis, including potentially serious complications such as clinically compromising anemia, acute renal insufficiency and disseminated intravascular coagulation. In some cases, these complications have been fatal. Most of these patients experienced symptoms of intravascular hemolysis within four hours of receiving the therapy.

Patients receiving WinRho SDF should contact their physicians immediately if they experience symptoms of hemolysis such as back pain, shaking chills, fever, or discolored urine. The company also has a new patient information sheet that describes these symptoms.

Duration : 0:1:3

Technorati Tags: anemia, Coagulation, Disseminated, Fatal, FDA, Hemolysis, Insufficiency, Intravascular, patient, Renal, Safety, SDF, WinRho